$2.25T
Total marketcap
$120.91B
Total volume
BTC 50.11%     ETH 15.69%
Dominance

Eli Lilly and Company LLY.SW Stock

705 CHF {{ price }} 0.000000% {{change_pct}}%
Exchange
Swiss
Market Cap
670.29B CHF
LOW - HIGH [24H]
695 - 695 CHF
VOLUME [24H]
13 CHF
{{ volume }}
P/E Ratio
133.27
Earnings per share
5.29 CHF

Eli Lilly and Company Price Chart

Eli Lilly and Company LLY.SW Financial and Trading Overview

Eli Lilly and Company stock price 705 CHF
Previous Close 530 CHF
Open 530 CHF
Bid 260 CHF x 0
Ask 590 CHF x 0
Day's Range 535 - 535 CHF
52 Week Range 274 - 560 CHF
Volume 18.58K CHF
Avg. Volume 854 CHF
Market Cap 503.13B CHF
Beta (5Y Monthly) 0.331
PE Ratio (TTM) 109.9585
EPS (TTM) 5.29 CHF
Forward Dividend & Yield 4.55 (0.85%)
Ex-Dividend Date February 14, 2024
1y Target Est N/A

LLY.SW Valuation Measures

Enterprise Value 494.43B CHF
Trailing P/E 109.9585
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 15.687356
Price/Book (mrq) 42.47816
Enterprise Value/Revenue 15.416
Enterprise Value/EBITDA 43.692

Trading Information

Eli Lilly and Company Stock Price History

Beta (5Y Monthly) 0.331
52-Week Change N/A
S&P500 52-Week Change N/A
52 Week High 560 CHF
52 Week Low 274 CHF
50-Day Moving Average 536.08 CHF
200-Day Moving Average 435.31 CHF

LLY.SW Share Statistics

Avg. Volume (3 month) 854 CHF
Avg. Daily Volume (10-Days) 2 CHF
Shares Outstanding 949.31M
Float 897.74M
Short Ratio N/A
% Held by Insiders 0.15%
% Held by Institutions 84.37%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 4.37
Trailing Annual Dividend Yield 0.82%
5 Year Average Dividend Yield 155.00%
Payout Ratio 0.7917
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) September 30, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 15.55%
Operating Margin (ttm) 37.27%
Gross Margin 78.66%
EBITDA Margin 35.28%

Management Effectiveness

Return on Assets (ttm) 11.62%
Return on Equity (ttm) 46.46%

Income Statement

Revenue (ttm) 32.07B CHF
Revenue Per Share (ttm) 35.62 CHF
Quarterly Revenue Growth (yoy) 36.79%
Gross Profit (ttm) 21.91B CHF
EBITDA 11.32B CHF
Net Income Avi to Common (ttm) 4.99B CHF
Diluted EPS (ttm) 4.82
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 2.62B CHF
Total Cash Per Share (mrq) 2.92 CHF
Total Debt (mrq) 20.33B CHF
Total Debt/Equity (mrq) 179.81 CHF
Current Ratio (mrq) 1.046
Book Value Per Share (mrq) 12.477

Cash Flow Statement

Operating Cash Flow (ttm) 5.71B CHF
Levered Free Cash Flow (ttm) 3.9B CHF

Profile of Eli Lilly and Company

Country Switzerland
State IN
City Indianapolis
Address Lilly Corporate Center
ZIP 46285
Phone 317 276 2000
Website https://www.lilly.com
Industry Drug Manufacturers-General
Sector(s) Healthcare
Full Time Employees 39000

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; Foghorn Therapeutics Inc., and PRISM BioLab Co.,Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Q&A For Eli Lilly and Company Stock

What is a current LLY.SW stock price?

Eli Lilly and Company LLY.SW stock price today per share is 705 CHF.

How to purchase Eli Lilly and Company stock?

You can buy LLY.SW shares on the Swiss exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Eli Lilly and Company?

The stock symbol or ticker of Eli Lilly and Company is LLY.SW.

Which industry does the Eli Lilly and Company company belong to?

The Eli Lilly and Company industry is Drug Manufacturers-General.

How many shares does Eli Lilly and Company have in circulation?

The max supply of Eli Lilly and Company shares is 950.77M.

What is Eli Lilly and Company Price to Earnings Ratio (PE Ratio)?

Eli Lilly and Company PE Ratio is 133.27032000 now.

What was Eli Lilly and Company earnings per share over the trailing 12 months (TTM)?

Eli Lilly and Company EPS is 5.29 CHF over the trailing 12 months.

Which sector does the Eli Lilly and Company company belong to?

The Eli Lilly and Company sector is Healthcare.